Drugs / BAY79-4980
BAY79-4980
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00629837 | Sep 2005 → Mar 2006 | hemophilia A | Bayer | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00623727 | Jun 2008 → Apr 2010 | hemophilia A | Bayer | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 79-4980 | “BAY 79-4980 is an investigational drug consisting of rFVIII-FS (sucrose-formulated recombinant FVIII) reconstituted with liposome solvent.” PMID 23014711 ↗ Sep 20123“Low dose of BAY 79-4980 [13mg of liposomes/kg] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).” NCT00629837 ↗ “Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)” NCT00629837 ↗ |
| Known as | Kogenate FS Liposome | “Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)” NCT00629837 ↗ |
| Known as | Recomb. Factor VIII | “Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)” NCT00629837 ↗ |
| Modality | Protein / enzyme biologic | “recombinant FVIII” PMID 20059562 ↗ Jan 2010 |
| Route | Intravenous | “35 IU/kg body weight intravenous 1x/week for 52 weeks” NCT00623727 ↗ |